{
  "pmcid": "9750631",
  "sha256": "dafc39e885e4bc0495c8e5d20645008355bc94f77060faacf2f4db352a87649c",
  "timestamp_utc": "2025-11-09T16:22:12.737412+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.404799811587377,
    "reading_ease": 51.71574187470563,
    "word_count": 772
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The double-blind, randomized, placebo-controlled phase 3 study of orally administered PLX3397"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "ENLIVEN was a phase 3 randomized, placebo-controlled clinical trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "adults with TGCT not amenable to improvement with surgery received pexidartinib or placebo for 24 weeks"
      },
      "Intervention": {
        "score": 2,
        "evidence": "received pexidartinib or placebo for 24 weeks"
      },
      "Objective": {
        "score": 1,
        "evidence": "What level of pain relief was achieved by pexidartinib treatment in ENLIVEN?"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "primary definition of a pain response was a decrease of at least 30% in the weekly mean worst-pain NRS score and increase of less than 30% in narcotic analgesic use between baseline and week 25"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "121 were randomized (50% [60] to placebo, 50% [61] to pexidartinib)"
      },
      "Blinding": {
        "score": 3,
        "evidence": "The double-blind, randomized, placebo-controlled phase 3 study"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "121 were randomized (50% [60] to placebo, 50% [61] to pexidartinib)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "120 were given either placebo or pexidartinib (59 received placebo and 61 received pexidartinib) and were included in an intent-to-treat analysis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "response percentage 31% [19 of 61] [95% CI 21% to 44%] versus 15% [9 of 59] [95% CI 8% to 27%]; one-sided p = 0.03"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}